Abbott Laboratories Stock
€106.10
Your prediction
Abbott Laboratories Stock
Pros and Cons of Abbott Laboratories in the next few years
Pros
Cons
Performance of Abbott Laboratories vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Abbott Laboratories | -0.360% | -5.903% | -7.841% | 13.506% | -2.669% | -1.771% | 24.991% |
Elanco Animal Health Inc. | 0.000% | -1.662% | 7.212% | 7.433% | 8.642% | -37.830% | -38.919% |
Johnson & Johnson | 0.460% | 4.580% | 8.167% | -1.097% | 1.136% | -16.154% | 8.250% |
Pfizer Inc. | 1.690% | -4.419% | -0.216% | -24.601% | -18.151% | -58.553% | -31.391% |

sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Examining the financials of the pharmaceutical giant Abbott Laboratories, with its ticker symbol ABT, one can't help but form an initial impression tinged with intrigue. Abbott stands as a prominent entity in the healthcare sector, known for its diversified portfolio ranging from medical devices to nutritional products and branded generic medications. This diversity is reflected in its robust financial statements, showcasing the company's significant market presence and operational efficiency.
The sheer magnitude of Abbott's total assets, which hovered consistently above the $70 billion mark from 2020 to 2022, signals a company with considerable resources and a solid financial foundation. Across the same period, the evolution of its balance sheet reveals a healthy balance between liabilities and stockholder equity, pointing to sound financial management. The company's liquidity, as illustrated by its cash reserves, provides confidence in Abbott's ability to meet short-term obligations and invest in growth opportunities.
Profitability and Revenue Streams Abbott has demonstrated an admirable profit margin and a stable operating margin, hinting at its efficiency in converting revenue into profit and managing its operational expenses. The company's net income has shown relative growth, especially when evaluating the year-over-year rise from 2020 to 2022, indicating a consistent upward trajectory in profitability.
Comments
News

Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield
If you wonder whether Abbott Laboratories (NYSE: ABT) is a good buy in Q2 2025, the answer is yes. The company’s management, portfolio, cash flow, capital return, and pipeline are why. The stock

Abbott Reports 10.5% EPS Growth for Fiscal Q2
Abbott Laboratories (NYSE:ABT), a global healthcare company known for its medical devices, diagnostics, nutrition, and pharmaceuticals, reported fiscal 2025 earnings on Thursday, July 17, that

Abbott (ABT) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.
Need a quote from one of our analysts? Email [email protected]
Abbott Laboratories (NYSE:ABT) presented a quarter marked by distinct segment divergence, with medical devices